Cell Signaling Technology

Product Pathways - Protein Stability

Ubiquitin Antibody #3933

Applications Reactivity Sensitivity Source
W IHC-P H M R (Mk) (Dm) (X) (Z) (B) (Pg) (Hr) Endogenous Rabbit

Applications Key:  W=Western Blotting  IHC-P=Immunohistochemistry (Paraffin)
Reactivity Key:  H=Human  M=Mouse  R=Rat  Mk=Monkey  Dm=D. melanogaster  X=Xenopus  Z=Zebrafish  B=Bovine  Pg=Pig  Hr=Horse
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

Ubiquitin Antibody detects ubiquitin, polyubiquitin and ubiquitinated proteins. This antibody may cross-react with recombinant NEDD8.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to the amino terminus of the human ubiquitin protein. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa and NIH/3T3 cells, untreated or treated with the proteasome inhibitor MG132 (10 µM for 90 minutes), using Ubiquitin Antibody.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human breast carcinoma using Ubiquitin Antibody in the presence of control peptide (left) or antigen-specific peptide (right).

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human lung carcinoma using Ubiquitin Antibody.


Background

Ubiquitin is a conserved polypeptide unit that plays an important role in the ubiquitin-proteasome pathway. Ubiquitin can be covalently linked to many cellular proteins by the ubiquitination process, which targets proteins for degradation by the 26S proteasome. Three components are involved in the target protein-ubiquitin conjugation process. Ubiquitin is first activated by forming a thiolester complex with the activation component E1; the activated ubiquitin is subsequently transferred to the ubiquitin-carrier protein E2, then from E2 to ubiquitin ligase E3 for final delivery to the epsilon-NH2 of the target protein lysine residue (1-3). The ubiquitin-proteasome pathway has been implicated in a wide range of normal biological processes and in disease-related abnormalities. Several proteins such as IκB, p53, cdc25a and Bcl-2 have been shown to be targets for the ubiquitin-proteasome process as part of regulation of cell cycle progression, differentiation, cell stress response, and apoptosis (4-7).

  1. Ciechanover, A. (1998) EMBO J. 17, 7151-7160.
  2. Hochstrasser, M. (2000) Nat. Cell Biol. 2, E153-E157.
  3. Hochstrasser, M. (2000) Science 289, 563-564.
  4. Bernardi, R. et al. (2000) Oncogene 19, 2447-2454.
  5. Aberle, H. et al. (1997) EMBO J. 16, 3797-3804.
  6. Salomoni, P. and Pandolfi, P.P. (2002) Nat. Cell Biol. 4, E152-E153.
  7. Jesenberger, V. and Jentsch, S. (2002) Nat. Rev. Mol. Cell Biol. 3, 112-121.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.

Products